LEO Pharma Inc. announced today the availability of the Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in ...

A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic dermatitis not adequately controlled with topical ...

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...

IL-13 inhibitor tralokinumab has been cleared by the US regulator as Adbry as a treatment for moderate-to-severe atopic dermatitis in adults who can't control symptoms using topical prescription ...

One such biologic medicine for atopic dermatitis is Adbry (tralokinumab), which was approved by the FFDA in 2021. It comes as a liquid solution that is injected under the skin. Atopic dermatitis ...

Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market. However, ...

Dupixent is an antibody engineered to block two signaling pathways, IL-13 and IL-14. LEO Pharma’s Adbry, an antibody designed to block IL-13, won FDA approval in atopic dermatitis in 2021.

Eli Lilly and Co.’s Ebglyss (lebrikizumab) becomes the latest U.S. entrant in the increasingly competitive atopic dermatitis space, following FDA approval of the IL-13-targeting antibody, which will ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Common biologics used for eczema treatment include Dupixent (dupilumab) and Adbry (tralokinumab-ldrm). Your dermatologist may ...

LEO Pharma Inc. announced today the availability of the Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in the United States. Adbry is currently indicated in the U.S. for patients ...